February 14, 2019 VACCIBODY AS – NOK 230 MILLION (EUR 23.6 MILLION) PRIVATE PLACEMENT SUCCESSFULLY PLACED
Reference is made to the press release by Vaccibody AS (“Vaccibody” or the “Company”) on 13 February 2019 regarding a contemplated offer of new shares (the “Offer Shares”) in a private placement to raise gross proceeds of approximately NOK 230 million (the “Private Placement”). The Company is pleased to announce that the Private Placement has been successfully placed, raising gross proceeds of NOK 230 million by allocating 5,750,000 shares at a subscription price of NOK 40.00 per Offer Share. The Private Placement received strong interest from existing shareholders and new investors. The net proceeds from the Private Placement will i.a. be used to conduct a Phase IIa clinical study combining Vaccibody’s product candidate VB10.16 with Roche’s checkpoint inhibitor Atezolizumab, prepare for expansion cohorts in Vaccibody’s VB10.NEO cancer neoantigen programme and initiation of two expansion cohorts, as well as for general corporate purposes.
Notification of allocation of Offer Shares is expected to be sent on or about 14 February 2019. Completion of the Private Placement by the delivery of the Offer Shares is subject to (i) final resolutions by the Board, (ii) shareholder approval at the Extraordinary General Meeting in the Company, expected to be held on 21 February 2019 and (iii) the registration of the share capital increase pertaining to the Private Placement with the Norwegian Register of Business Enterprises and issuance of the Offer Shares by the VPS (jointly, the “Conditions”).
Following registration of the share capital increase pertaining to the Private Placement, the Company will have a share capital of NOK 2,711,494, divided into 54,229,880 shares, each with a nominal value of NOK 0.05. In addition, there are 4,128,369 outstanding warrants issued to key personnel.
ABG Sundal Collier ASA and Arctic Securities AS acted as Joint Bookrunners (together, the “Managers”) in the Private Placement.
For further information, please contact:
Martin Bonde, CEO
+45 2025 3560
About Vaccibody AS
Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. A phase I/IIa neoantigen clinical trial is currently enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial or squamous cell carcinoma of the head and neck. Vaccibody’s front runner program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), which has reported positive 6M interim data, evaluates the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).